Clinical Trial Update: Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of VK 2019, a novel EBNA1 inhibitor, in EBV-positive nasopharyngeal carcinoma and other EBV-associated cancers, including PK/PD co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-associated Carcinoma
• Nasopharyngeal Carcinoma

Drugs mentioned

• VK 2019 (VK-2019 EBNA1 inhibitor)

Snippet

Sponsor: Stanford University | Conditions: Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING